Asklepios BioPharmaceutical, Inc. (AskBio)
78 articles about Asklepios BioPharmaceutical, Inc. (AskBio)
-
Sheila Mikhail, AskBio CEO and Cofounder, Named Springboard Enterprises' 2019 Northstar Honoree
10/24/2019
National award recognizes outstanding entrepreneurial women who lead high-growth companies that are transforming their industries
-
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
10/15/2019
This collaboration brings together AskBio’s leading capsid development, clinical stage AAV vector delivery system, and manufacturing expertise with Editas Medicine’s leading genome editing technologies to potentially develop novel medicines for patients with high unmet need.
-
AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV Gene Therapeutics
9/17/2019
Asklepios BioPharmaceutical, Inc. (AskBio), a fully integrated Adeno-Associated Virus (AAV) gene therapy platform company focused on providing curative therapeutics for genetic disorders, has acquired the technology assets of RoverMed BioSciences.
-
AskBio Acquires Synpromics Ltd. and Expands its Gene Therapy Technology Portfolio
8/13/2019
Synpromics to operate as a wholly owned subsidiary; the two companies bring together pioneering technology to increase efficacy of gene therapeutics
-
Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation
8/1/2019
Vida More than Triples Assets Under Management in Less than Two Years to Approximately $1 Billion Based on Success of Inaugural Fund and Focus on Funding Transformational Science
-
AskBio Partners with TPG and Vida Ventures
4/11/2019
Leading gene therapy company announces $235 million investment to accelerate growth
-
The investment, which includes $225 million from Vida Ventures and TPG, as well as $10 million from AskBio’s founders and board members, is earmarked to advance and expand clinical trials.
-
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
-
Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics.
-
Asklepios Looks for 6-Figure Incentive Package to Create 150 New Jobs
10/9/2017
-
Asklepios BioPharmaceutical, Inc. Enters Into License Agreement With Calimmune
1/12/2016
-
Asklepios BioPharmaceutical, Inc. And AveXis Finalize License
6/17/2015
-
Asklepios BioPharmaceutical, Inc. Executes License With Benitec Limited
4/16/2015
-
Asklepios BioPharmaceutical, Inc. Enters Cross-License Agreement With Genzyme Corporation
7/16/2013
-
REGENX Biosciences, LLC and Asklepios BioPharmaceutical, Inc. Enter Into Agreement for the Development of Treatments for Hemophilia A Using NAV(TM) rAAV8 Vectors
3/8/2012
-
Asklepios BioPharmaceutical, Inc. Enters Into A Patent License Agreement With Pfizer Inc.
9/13/2010
-
Asklepios BioPharmaceutical, Inc.: Non-Profit Founded to Advance Orphan Drug Research
9/25/2007
-
Asklepios BioPharmaceutical, Inc.. Announces Cross License With GlaxoSmithKline
9/28/2006